HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

recommendations are presented for the diagnosis and management of eosinophilic esophagitis (EoE). Evan S. Dellon, M.D., M.P.H., from the University of North Carolina School of Medicine in Chapel ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the inflammatory and fibrostenotic aspects of the disease.

Suggested treatments for eosinophilic esophagitis include proton pump inhibitors ... but currently available allergy testing to direct food elimination diets is not suggested. Dupilumab is suggested ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...